Cancer Therapy Sends 5 Lupus Patients Into Remission

Five people with severe lupus are now living symptom-free after receiving a revolutionary therapy originally designed to fight cancer, marking what could be the beginning of the end for an incurable disease affecting 1.5 million Americans.

Katie Tinkler's heart, lungs, and kidneys were all failing from lupus nephritis two years ago. Today, she's skiing in the Alps and dancing at her daughter's wedding. "My life two years ago versus now, it's unrecognizable," she told The Guardian.

Tinkler was one of nine patients treated at University College London Hospital with CAR T-cell therapy, a Nobel Prize-winning approach that reprograms a patient's own white blood cells. The therapy has revolutionized cancer treatment over the past decade, and now it's showing promise for autoimmune diseases too.

Here's how it works: doctors remove white blood cells from a patient's blood and genetically modify them to target specific cells. For cancer patients, those reprogrammed cells hunt down malignancies hiding from the immune system. For lupus patients, the therapy appears to reset the entire immune system, stopping it from attacking healthy organs.

The results surprised even the researchers. Five of the six patients who received a lower dose went into complete remission within just three months. They've stayed there for over 11 months with no signs of the disease returning.

Lupus is an autoimmune disorder where the immune system mistakes healthy cells for invaders and attacks them. In lupus nephritis, the kidneys become the target, leading to debilitating fatigue, joint pain, organ damage, and sometimes death. Until now, patients faced a lifetime of powerful immunosuppressant drugs that come with serious side effects.

The Ripple Effect

The implications stretch far beyond lupus. CAR T-cell therapy's success with this autoimmune disease suggests it could work for others too, from rheumatoid arthritis to multiple sclerosis. The therapy essentially teaches the immune system to start over, breaking the cycle of chronic disease.

"These findings are truly groundbreaking and offer fresh hope to people living with lupus," said Professor Karl Peggs, director of UCLH's biomedical research center. "If these results are confirmed in larger studies, the prospect of a cure for lupus may no longer be out of reach."

The three patients who received higher doses are still being monitored to determine the optimal treatment level. Researchers emphasize that larger studies are needed before this becomes widely available, but the early results represent what Peggs calls "a remarkable step forward."

For Tinkler and the others in remission, the future looks completely different than it did just two years ago.